Tmic-30. role of matrix metalloproteinase 9 (mmp9) in resistance to anti-angiogenic therapy

CONCLUSIONS:These findings challenge the ideas that gelatinases are solely downstream targets of higher level regulators and that neutrophils are passive inflammatory bystanders, instead defining neutrophil-secreted MMP9 as an early activator responsible for downstream effects driving resistance to anti-angiogenic therapy.

Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Yagnik, G., Kuang, R., Jahangiri, A., Chen, W., Aghi, M. Tags: TUMOR MICROENVIRONMENT Source Type: research